To assess the metabolic consequences of hemipancreatectomy in humans, we determined pancreatic beta and alpha cell function in healthy donors. Donors examined cross-sectionally were found to have significantly decreased glucose-induced phasic insulin secretion and arginine-induced insulin and glucagon secretion as compared to age, sex, and body index-matched controls. However, their fasting glucose and insulin values were not different from controls. Similar observations were found in the prospective evaluation of eight donors before and 15±2 mo after hemipancreatectomy. Beta cell reserve, as measured by glucose potentiation of arginine-induced insulin secretion, was significantly decreased in donors (maximal acute insulin response [AIR..]: donors = 666±84 pM vs controls = 1,772±234 pM) while the PG5, (the glucose value at which the half-maximal response was observed) was the same in the two groups. Donors and controls responded to 60-min continuous intravenous infusions of glucose by reaching identical serum glucose values, despite significantly lower insulin secretory responses in donors. We conclude that hemipancreatectomy in human donors is associated with decreased pancreatic alpha and beta cell function. Since donors generally maintain normoglycemia after hemipancreatectomy despite diminished insulin secretion, our data suggest that healthy humans may compensate for hemipancreatectomy by increasing glucose disposal. (J. Clin. Invest. 1992. 89:1761-1766
Introduction
The use of living related donors in human transplantation has become a treatment ofchoice for individuals in kidney failure, but controversy remains about their use in patients with failing pancreata, livers, or lungs. Consequently, hemipancreatectomy for the purpose of organ donation to a diabetic family member remains an active part of only a few pancreas transplantation programs around the world. Although the serum glucose values after hemipancreatectomy in humans have been found to be elevated as compared to values obtained before surgery (1, 2) , and while as many as 25% of human donors develop abnormal glucose tolerance after surgery (2), the effects of this operation on beta cell function have been only superficially examined (2) while no information about alpha cell function has been reported.
Preoperatively, human pancreas donors, like other healthy individuals, maintain normoglycemia through a precise balance between insulin secretion and insulin action. At the time ofsurgery, donors experience a sudden and dramatic reduction in their beta and alpha cell mass. Such a reduction may result in significantly decreased hormone secretion, as has been documented in dogs (3) and rats (4) , and may require alterations in hormone action for the maintenance ofeuglycemia. Therefore, understanding how hemipancreatectomized human donors regulate glucose homeostasis in the face of an abrupt loss of pancreatic islet tissue may provide insights into the pathogenesis oftype II diabetes mellitus, a disorder characterized both by defects in insulin secretion and insulin action. Consequently, we have performed a detailed evaluation of pancreatic endocrine function in healthy human donors after hemipancreatectomy at the University of Minnesota and compared them to controls with and without a history of type I diabetes in a first degree relative. The specific aims of our investigation were: (a) to determine the effect of hemipancreatectomy on insulin secretion after intravenous pulses of glucose and arginine; (b) to ascertain the adequacy of beta cell reserve after hemipancreatectomy using the technique of glucose potentiation of arginine-induced insulin secretion to determine both the maximal insulin secretory response and the glucose value at which the half-maximal response is observed (PG50);' (c) to determine the effect of partial pancreatectomy on glucoregulation during intravenously administered glucose given as both a pulse and a continuous infusion; and (d) to assess the effects ofpartial pancreatectomy on alpha cell function as determined by the glucagon secretory response to arginine injection at basal glucose and during experimentally produced hyperglycemia.
Methods
Patient selection. Hemipancreatectomized individuals were recruited from patients who have served as pancreas organ donors at the University of Minnesota. As of June 1, 1991, 75 first degree relatives of patients with type I diabetes mellitus have participated as donors in the pancreas transplant program. Details of their preoperative evaluation and the surgical procedure are included in an earlier publication (2) . Donors receiving medical therapy for clinical diabetes were excluded from participation. Healthy controls were selected to match the donors with respect to age, sex, and body mass index. In control group 1, no member had a family history of diabetes in a first degree relative. In control group 2, members were all first degree relatives of someone with type I diabetes mellitus. Our protocol was approved by the Committee on the Use of Human Subjects in Research at the University of Minnesota, and all participants provided written consent.
Metabolic evaluation. All testing was performed in the General Clinical Research Center at the University of Minnesota after the subjects had fasted for at least 10 h. Beginning at 8 a.m. patients underwent an intravenous arginine stimulation test followed 30 min later by either an intravenous glucose tolerance test or the glucose potentiation study detailed below. The insulin secretory response to an intravenous injection of glucose and the glucose disappearance rate (Kg) were assessed on a separate morning in some patients. The intravenous glucose tolerance test was performed by the administration of20 g ofglucose (given as dextrose 50 gm per 100 ml water) over 30 s, with time zero set at half-way through the injection volume. Samples for glucose and insulin were obtained at -10, -5, 0, 2, 3, 4, 5, 7, 10, 15, 20, 25, and 30 min. The arginine stimulation tests were performed by the intravenous administration of 5 g of arginine (given as 10% arginine HCI; Kabi Vitrum, Inc., Clayton, NC) over 30 s, with time zero set at the time at which one-halfofthe injection volume was given. Samples for glucose, insulin, and glucagon were obtained at -10, -5, 0, 2, 3, 4, 5, 7, and 10 min.
The glucose potentiation study was modified from that previously described (5, 6) to determine more precisely the glucose value at which the insulin secretory response was half-maximal (PGm) in our donor population. In our modification, five arginine stimulation tests were done at different levels of serum glucose. The serum glucose values at which the arginine stimulation tests were performed were baseline, those levels achieved by continuous infusion ofglucose (as dextrose 10 gm per 100 ml water) for 1 h at rates of 300 mg/min, 600 mg/min, 900 mg/min, and a final infusion of dextrose 20 gm per 100 ml water at a variable rate calculated to bring to serum glucose to 27.8 mM, as described by Ward and colleagues (7) . The continuous infusion ofglucose at rates of 300 mg/min, 600 mg/min, and 900 mg/min allowed us to compare the donors and the controls with respect to their glycemic responses to fixed infusions of glucose. Before beginning the study, intravenous lines were placed in both arms of the subjects. The arm from which blood was sampled was placed in a warming chamber heated to 55OC at least 30 min before the study to assure arterialization ofthe venous blood (8) . A 2-h rest period was allowed between each of the glucose potentiation studies to allow the patient's serum glucose, insulin, and glucagon to return to baseline (6) . Subjects studied via this protocol included the 10 donors studied cross-sectionally, the 10 members of the first control group, and 6 members ofthe second control group. No donors were followed prospectively using the glucose potentiation protocol.
Determination of serum glucose, insulin, and glucagon values. Serum glucose values were determined by the glucose oxidase method using an autoanalyzer (Beckman Instruments, Inc., Fullerton, CA). Serum insulin values were measured by radioimmunoassay as previously described (9) . Samples for glucagon determinations were collected into prechilled tubes containing 2.5 mg EDTA and 500 U Trasylol (Miles, Inc., FBA Pharmaceuticals, West Haven, CT) per milliliter blood, put on ice, and centrifuged immediately. Glucagon was measured by radioimmunoassay (10) The maximal acute insulin response (AIR.) was taken as the secretory response measured at a serum glucose 2 27.8 mM. The glucose value at which the secretory response was half-maximal (PGjo) was estimated from graphs ofindividual glucose potentiation data and then meaned within groups. In all subjects this determination was aided by the use of a computer generated line demonstrating the relationship between AIR and serum glucose concentration. Accuracy of the PG50 determination was assured by the presence of at least two studies at glucose concentrations at or above that at which glucose maximally potentiated arginine-induced insulin secretion. Differences between groups were assessed using the nonparametric one-tailed Mann Whitney U Test (for single values of glucose, insulin, glucagon, glucose disappearance rates, and acute hormonal secretion) or a two-way analysis of variance (ANOVA) (for data from intravenous glucose tolerance tests, arginine stimulation tests of insulin and glucagon secretion, and glucose potentiation). A P value equal to or less than 0.05 was considered statistically significant.
Results
Subject characteristics. 10 donors were studied 69±12 mo (mean±SEM) after hemipancreatectomy (Table I) . They were matched with respect to sex, age, and body mass index with two groups of 10 healthy controls that differed in their family history of type I diabetes mellitus (listed under Cross-sectional Data in Table I ). Subjects in control group 1 were without a family history of type I diabetes, whereas subjects in control group 2 had a first degree relative with type I diabetes. An additional eight donors were studied before and 15±2 mo after hemipancreatectomy (listed under Prospective Data in Table  I (Table I) . However, the postoperative Kg values of donors followed prospectively were significantly less than the preoperative values (Table I, Fig. 2) .
The insulin secretory response to arginine was also significantly decreased in the donors when compared to the matched donors studied prospectively (Fig. 4) Alpha cell function. Alpha cell function was assessed by measuring the glucagon secretory response to the intravenous administration ofarginine. No differences were observed when comparing basal glucagon values in the donors (84±9 ng/liter, n = 10), control group 1 (105±13 ng/liter, n = 10), and control group 2 (72±27 ng/liter, n = 7). The acute glucagon response to arginine at basal glucose levels was significantly decreased in donors compared to their matched controls (90±8 ng/liter in donors vs 256±42 ng/liter in control group 1 [n = 10, P < 0.001] and 181±30 ng/liter in control group 2 [n = 7, P < 0.05], P = 0.001, Fig. 7) . Hyperglycemia during the glucose potentiation studies significantly inhibited arginine-induced glucagon secretion in both donors and controls (P < 0.001, Fig.   8 SERUM GLUCOSE, mM (at end of glucose infusio Figure 6 . Response of donors and controls to continuous intravenous glucose infusions. Arginine stimulation tests were performed at basal glucose, after 60-min continuous infusions of glucose at rates of 300 mg/min, 600 mg/min, and 900 mg/min, and after a variable infusion of glucose calculated to bring serum glucose to . 27.8 mM. In response to these infusions, donors (o, n = 10) and matched controls (-, control group 1, n = 10; *, control group 2, n = 6) achieved the same glucose values (A).
The insulin values achieved after the glu-4 0 cose infusions were significantly lower in the donors than in the controls (P < 0.001, on) B).
cose tolerance tests and that this is associated with diminished insulin responses to oral glucose. Earlier, Bolinder and colleagues observed decreased glucose-induced insulin secretion and rates of glucose disappearance in two subjects 12 mo after hemipancreatectomy (1) . In our investigation, we have determined glucose-induced insulin responses to intravenous glucose to be significantly decreased in 10 donors studied a mean of 69±12 mo after organ donation as compared to matched controls, and have confirmed the validity ofthese observations by comparing them to data obtained from studies ofeight subjects examined before and 15±2 mo after hemipancreatectomy. Moreover, we have assessed in vivo measures ofbeta cell reserve in donors using the technique ofglucose potentiation of arginine-induced insulin secretion. Our observations in humans confirms the experimental evidence in animals (3, 11) that partial pancreatectomy leads to a decrease in the functional reserve of the beta cell.
Our studies demonstrate that the beta cell dysfunction found after hemipancreatectomy is a global rather than a secretagogue-specific phenomenon since both glucose and arginineinduced insulin secretion were significantly decreased in donors compared to their matched controls. These data confirm those from dogs reported by Ward and colleagues (3) after a two-thirds pancreatectomy, but are in conffict with data from Bonner-Weir and colleagues (4) . Our disagreement with the latter group could be attributed to the species difference in our models (human vs weanling rat).
Arginine-induced glucagon secretion at both basal and elevated glucose values was found to be significantly lower in hemipancreatectomized subjects than controls. Since the majority of pancreatic glucagon is contained in the body and tail of the human pancreas (12) , distal pancreatectomy might be expected to diminished glucagon secretion. Our observations confirm the report of Gotoh et al. (13) that glucagon secretion is decreased after resection of the distal half of the pancreas from dogs. The functional significance ofdiminished glucagon secretion after partial pancreatectomy is uncertain, but the maintenance of a nearly normal insulin to glucagon ratio may facilitate normal glucose regulation.
After hemipancreatectomy, a statistically insignificant rise in the fasting glucose levels of both donor groups was noted. While the clinical significance of this rise is uncertain, it is worth considering that with time, hemipancreatectomized patients may become susceptible to the effects of "glucose toxicity." According to the glucose toxicity hypothesis, which has gained strong experimental support (14) (15) (16) (17) (18) (19) (20) insulin resistance seen with diabetes. Ifthe glucose toxicity hypothesis is correct, the relative hyperglycemia seen after partial pancreatectomy may eventually lead to decreased insulin secretion and to decreased glucose disposal. While decreased insulin secretion was observed in our donor group, our investigation cannot determine whether this was due to the surgically induced decrease in beta cell mass or to potentially adverse effects of chronic, relative hyperglycemia. However, our data suggest that hemipancreatectomized humans may increase, rather than decrease, glucose utilization after surgery. Since total glucose disposal is equal to the sum of insulin-dependent and glucose-dependent mechanisms ofglucose uptake (24, 25) , careful study of human donors after hemipancreatectomy should provide important insights into the relative contributions of beta cell secretion, insulin-mediated glucose uptake, and glucose-mediated glucose uptake to the overall maintenance of normoglycemia. In addition, long-term follow-up of hemipancreatectomized donors, especially of those who develop hyperglycemia, is likely to provide fresh insights into the glucose toxicity hypothesis. Our observations are clinically relevant for pancreas transplantation programs using living related human donors. Previous investigation has demonstrated that 25% of such donors develop impaired glucose tolerance or frank diabetes within one year ofthe operation (2) . The current report demonstrates that all donors are likely to experience a significant decrease in both alpha and beta cell function. While the long-term consequences of these changes in pancreatic endocrine function are unknown, prudence dictates that cadaver donors be used for pancreas transplantation in all but the most exceptional circumstance, such as when a suitable cadaveric organ cannot be located for a patient with a very pressing need for a new pancreas.
In 
